Cornerstone taps Chiesi link as it hones hospital focus with anti-infective
This article was originally published in Scrip
Cornerstone Therapeutics' stock price ticked slightly higher on 8 November, but closed down 0.6% on news that the Cary, North Carolina-based company licensed exclusive US rights to Chiesi Farmaceutici's recently approved Bethkis (tobramycin inhalation solution) to treat chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.